Rimonabant
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
Sanofi · Phase 3 · Completed · Enrollment 1507
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Registry arm not named | n/r | n/r | n/r | n/r |
Not shown
- Registry arm not named: endpoint not reported